Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cartesian Therapeutics, Inc.RNAC · Entity 6015 | Director · 10% owner | January 02, 2026 | January 06, 2026 |
| Tectonic Therapeutic, Inc.TECX · Entity 5328 | Director · 10% owner | June 09, 2026 | June 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cartesian Therapeutics, Inc.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,646,285 |
Reported balance
After 2026-01-02 transaction · row 1
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 2,600 · Balance 8,646,285 F1: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in full on January 2, 2027. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.76 · Expires 2036-01-01 | Direct | 7,800 |
Reported balance
After 2026-01-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-01-02 · Grant · Acquired 7,800 · Balance 7,800 |
| Common StockSEC Table I · non-derivative | IndirectBy wife | 330,695 |
Reported balance
Holding disclosure · report date 2026-01-02 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 330,695 |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 656,513 |
Reported balance
Holding disclosure · report date 2026-01-02 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 656,513 F2: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in full on January 2, 2027.
F2: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any.
Tectonic Therapeutic, Inc.
Report date June 09, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.56 · Expires 2036-06-08 | Direct | 10,200 |
Reported balance
After 2026-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 10,200 · Balance 10,200 F1: The option shall vest in full on the earliest of (i) June 9, 2027, (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, or (iii) a "Change in Control" (as defined in the Issuer's 2024 Equity Incentive Plan) of the Issuer, subject in each case, to the Reporting Person providing continuous service to the Issuer on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest in full on the earliest of (i) June 9, 2027, (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, or (iii) a "Change in Control" (as defined in the Issuer's 2024 Equity Incentive Plan) of the Issuer, subject in each case, to the Reporting Person providing continuous service to the Issuer on each such date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Morphic Holding, Inc.
Report date August 16, 2024 · Filed August 20, 2024
Section 16 reporting ended · disclosed 2024-08-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-08-16 transaction · row 1
1 source rowRow 1 · 2024-08-16 · Other · Disposed 4,608,052 · Balance 0 F1: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding. |
| Common StockSEC Table I · non-derivative | IndirectSee TAS Partners LLC | 0 |
Reported balance
After 2024-08-16 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2024-08-16 · Other · Disposed 2,768,893 · Balance 0 F1: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding. F3: The reporting person is the manager of TAS Partners LLC and has sole voting and dispositive power over such shares. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 0 |
Reported balance
After 2024-08-16 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2024-08-16 · Other · Disposed 42,873 · Balance 0 F1: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.76 · Expires 2029-04-11 | Direct | 0 |
Reported balance
After 2024-08-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-08-16 · Disposition to issuer · Disposed 4,288 · Balance 0 F5: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F4: The Company Stock Option ("Option") is fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2029-06-26 | Direct | 0 |
Reported balance
After 2024-08-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-08-16 · Disposition to issuer · Disposed 24,000 · Balance 0 F5: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F4: The Company Stock Option ("Option") is fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.72 · Expires 2029-12-05 | Direct | 0 |
Reported balance
After 2024-08-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-08-16 · Disposition to issuer · Disposed 90,000 · Balance 0 F5: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F4: The Company Stock Option ("Option") is fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.96 · Expires 2030-06-18 | Direct | 0 |
Reported balance
After 2024-08-16 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-08-16 · Disposition to issuer · Disposed 12,000 · Balance 0 F5: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F4: The Company Stock Option ("Option") is fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.79 · Expires 2031-06-16 | Direct | 0 |
Reported balance
After 2024-08-16 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2024-08-16 · Disposition to issuer · Disposed 9,996 · Balance 0 F5: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F4: The Company Stock Option ("Option") is fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.49 · Expires 2032-06-08 | Direct | 0 |
Reported balance
After 2024-08-16 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2024-08-16 · Disposition to issuer · Disposed 17,550 · Balance 0 F5: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F4: The Company Stock Option ("Option") is fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.47 · Expires 2033-05-31 | Direct | 0 |
Reported balance
After 2024-08-16 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2024-08-16 · Disposition to issuer · Disposed 12,535 · Balance 0 F5: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F4: The Company Stock Option ("Option") is fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.52 · Expires 2034-06-03 | Direct | 0 |
Reported balance
After 2024-08-16 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2024-08-16 · Disposition to issuer · Disposed 23,168 · Balance 0 F5: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F6: The Option will vest in full on the earlier of (a) June 04, 2025 and (b) the next annual meeting of the issuer's stockholders, subject to the reporting person's provision of service to the issuer on the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent.
F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding.
F3: The reporting person is the manager of TAS Partners LLC and has sole voting and dispositive power over such shares.
F4: The Company Stock Option ("Option") is fully vested.
F5: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof.
F6: The Option will vest in full on the earlier of (a) June 04, 2025 and (b) the next annual meeting of the issuer's stockholders, subject to the reporting person's provision of service to the issuer on the vesting date.
Scholar Rock Holding Corp
Report date December 10, 2019 · Filed December 12, 2019
Section 16 reporting ended · disclosed 2019-12-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,376,567 |
Reported balance
After 2019-12-10 transaction · row 1
1 source rowRow 1 · 2019-12-10 · Gift · Disposed 296,000 · Balance 2,376,567 F1: Represents shares of the Company's common stock transfered as a gift for no consideration to the Institute of Protein Innovation, a not-for-profit research institution. |
| Common StockSEC Table I · non-derivative | IndirectBy TAS Partners, LLC | 580,855 |
Reported balance
Holding disclosure · report date 2019-12-10 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 580,855 F2: Timothy Springer is the Managing Member of TAS Partners LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of the Company's common stock transfered as a gift for no consideration to the Institute of Protein Innovation, a not-for-profit research institution.
F2: Timothy Springer is the Managing Member of TAS Partners LLC.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 03, 2024 Filed Oct 4, 2024 21:58 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | PurchaseCommon Stock | 21,278 | $21.17 | $450,559.52 |
DisclosureSEC source: 0001453687-24-000115 · wk-form4_1728079086.xml · nonDerivative · entry 8 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,935,422 F7 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $20.78 to $21.77. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| October 03, 2024 Filed Oct 4, 2024 21:58 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | PurchaseCommon Stock | 50,489 | $20.18 | $1,018,878.12 |
DisclosureSEC source: 0001453687-24-000115 · wk-form4_1728079086.xml · nonDerivative · entry 7 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,914,144 F6 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $19.77 to $20.70. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| October 03, 2024 Filed Oct 4, 2024 21:58 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | PurchaseCommon Stock | 10,249 | $19.01 | $194,859.11 |
DisclosureSEC source: 0001453687-24-000115 · wk-form4_1728079086.xml · nonDerivative · entry 6 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,863,655 F5 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $18.76 to $19.74. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| October 03, 2024 Filed Oct 4, 2024 21:58 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | PurchaseCommon Stock | 29,847 | $18.25 | $544,576.42 |
DisclosureSEC source: 0001453687-24-000115 · wk-form4_1728079086.xml · nonDerivative · entry 5 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,853,406 F4 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $17.76 to $18.75. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| October 02, 2024 Filed Oct 4, 2024 21:58 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | OtherWarrant (Right to Buy) · Derivative | 20,045 | Not disclosed Strike: $46.50 | Not disclosed |
DisclosureSEC source: 0001453687-24-000115 · wk-form4_1728079086.xml · derivative · entry 16 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By wife Disclosed balance after: 20,045 Underlying: Common Stock · 20,045 shares Expires 2027-04-11 F1 · kind: Pro rata distribution for no consideration from TAS Partners LLC to the reporting person or the reporting person's spouse, as the case may be. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any. F1 · price: Pro rata distribution for no consideration from TAS Partners LLC to the reporting person or the reporting person's spouse, as the case may be. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any. Read SEC document |
| October 02, 2024 Filed Oct 4, 2024 21:58 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | OtherWarrant (Right to Buy) · Derivative | 113,587 | Not disclosed Strike: $46.50 | Not disclosed |
DisclosureSEC source: 0001453687-24-000115 · wk-form4_1728079086.xml · derivative · entry 15 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,587 Underlying: Common Stock · 113,587 shares Expires 2027-04-11 F1 · kind: Pro rata distribution for no consideration from TAS Partners LLC to the reporting person or the reporting person's spouse, as the case may be. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any. F1 · price: Pro rata distribution for no consideration from TAS Partners LLC to the reporting person or the reporting person's spouse, as the case may be. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any. Read SEC document |
| October 02, 2024 Filed Oct 4, 2024 21:58 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | OtherWarrant (Right to Buy) · Derivative | 133,632 | Not disclosed Strike: $46.50 | Not disclosed |
DisclosureSEC source: 0001453687-24-000115 · wk-form4_1728079086.xml · derivative · entry 14 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 33,408 Underlying: Common Stock · 133,632 shares Expires 2027-04-11 F1 · kind: Pro rata distribution for no consideration from TAS Partners LLC to the reporting person or the reporting person's spouse, as the case may be. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any. F1 · price: Pro rata distribution for no consideration from TAS Partners LLC to the reporting person or the reporting person's spouse, as the case may be. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any. F3 · ownership.nature: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any. Read SEC document |
| October 02, 2024 Filed Oct 4, 2024 21:58 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | OtherCommon Stock | 317,879 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001453687-24-000115 · wk-form4_1728079086.xml · nonDerivative · entry 4 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By wife Disclosed balance after: 330,695 F1 · kind: Pro rata distribution for no consideration from TAS Partners LLC to the reporting person or the reporting person's spouse, as the case may be. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any. F1 · price: Pro rata distribution for no consideration from TAS Partners LLC to the reporting person or the reporting person's spouse, as the case may be. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any. Read SEC document |
| October 02, 2024 Filed Oct 4, 2024 21:58 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | OtherCommon Stock | 2,119,193 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001453687-24-000115 · wk-form4_1728079086.xml · nonDerivative · entry 3 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 529,798 F1 · kind: Pro rata distribution for no consideration from TAS Partners LLC to the reporting person or the reporting person's spouse, as the case may be. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any. F1 · price: Pro rata distribution for no consideration from TAS Partners LLC to the reporting person or the reporting person's spouse, as the case may be. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any. F3 · ownership.nature: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any. Read SEC document |
| October 02, 2024 Filed Oct 4, 2024 21:58 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | PurchaseCommon Stock | 5,514 | $17.38 | $95,821.74 |
DisclosureSEC source: 0001453687-24-000115 · wk-form4_1728079086.xml · nonDerivative · entry 2 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,823,559 F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $17.17 to $17.50. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| October 02, 2024 Filed Oct 4, 2024 21:58 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | OtherCommon Stock | 1,801,314 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001453687-24-000115 · wk-form4_1728079086.xml · nonDerivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,818,045 F1 · kind: Pro rata distribution for no consideration from TAS Partners LLC to the reporting person or the reporting person's spouse, as the case may be. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any. F1 · price: Pro rata distribution for no consideration from TAS Partners LLC to the reporting person or the reporting person's spouse, as the case may be. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any. Read SEC document |
| September 26, 2024 Filed Sep 26, 2024 22:15 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | PurchaseCommon Stock | 2,400 | $30.87 | $74,088.00 |
DisclosureSEC source: 0001415889-24-024003 · form4-09262024_100948.xml · nonDerivative · entry 7 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,796,764 F7 · price: The reported price in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $30.80 to $30.90 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| September 26, 2024 Filed Sep 26, 2024 22:15 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | PurchaseCommon Stock | 4,070 | $30.10 | $122,507.00 |
DisclosureSEC source: 0001415889-24-024003 · form4-09262024_100948.xml · nonDerivative · entry 6 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,794,364 F6 · price: The reported price in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $29.75 to $30.63 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| September 26, 2024 Filed Sep 26, 2024 22:15 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | PurchaseCommon Stock | 18,999 | $29.13 | $553,440.87 |
DisclosureSEC source: 0001415889-24-024003 · form4-09262024_100948.xml · nonDerivative · entry 5 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,790,294 F5 · price: The reported price in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $28.69 to $29.68 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| September 26, 2024 Filed Sep 26, 2024 22:15 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | PurchaseCommon Stock | 24,531 | $28.16 | $690,792.96 |
DisclosureSEC source: 0001415889-24-024003 · form4-09262024_100948.xml · nonDerivative · entry 4 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,771,295 F4 · price: The reported price in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $27.68 to $28.66 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| September 25, 2024 Filed Sep 27, 2024 20:13 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | Exercise / conversionCommon Stock | 1,307 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001453687-24-000112 · wk-form4_1727468009.xml · nonDerivative · entry 6 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By wife Disclosed balance after: 12,816 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On September 20, 2024, the issuer held a special meeting of stockholders (the "Special Meeting"). At the Special Meeting, the stockholders of the issuer approved the conversion of the issuer's Series B Non-Voting Convertible Preferred Stock ("Series B Preferred Stock") into shares of common stock. On September 25, 2024, the conversion of the majority of the shares of Series B Preferred Stock occurred automatically (the "Automatic Conversion"). The remaining shares of Series B Preferred Stock remain subject to certain beneficial ownership limitations described in the issuer's filings with the Securities and Exchange Commission. At the time of the Automatic Conversion, all of the shares of Series B Preferred Stock beneficially owned by the reporting person converted into shares of common stock. Read SEC document |
| September 25, 2024 Filed Sep 27, 2024 20:13 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | Exercise / conversionSeries B Non-Voting Convertible Preferred Stock | 1,307 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001453687-24-000112 · wk-form4_1727468009.xml · nonDerivative · entry 5 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By wife Disclosed balance after: 0 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On September 20, 2024, the issuer held a special meeting of stockholders (the "Special Meeting"). At the Special Meeting, the stockholders of the issuer approved the conversion of the issuer's Series B Non-Voting Convertible Preferred Stock ("Series B Preferred Stock") into shares of common stock. On September 25, 2024, the conversion of the majority of the shares of Series B Preferred Stock occurred automatically (the "Automatic Conversion"). The remaining shares of Series B Preferred Stock remain subject to certain beneficial ownership limitations described in the issuer's filings with the Securities and Exchange Commission. At the time of the Automatic Conversion, all of the shares of Series B Preferred Stock beneficially owned by the reporting person converted into shares of common stock. Read SEC document |
| September 25, 2024 Filed Sep 27, 2024 20:13 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | Exercise / conversionCommon Stock | 721,361 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001453687-24-000112 · wk-form4_1727468009.xml · nonDerivative · entry 4 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 2,648,991 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On September 20, 2024, the issuer held a special meeting of stockholders (the "Special Meeting"). At the Special Meeting, the stockholders of the issuer approved the conversion of the issuer's Series B Non-Voting Convertible Preferred Stock ("Series B Preferred Stock") into shares of common stock. On September 25, 2024, the conversion of the majority of the shares of Series B Preferred Stock occurred automatically (the "Automatic Conversion"). The remaining shares of Series B Preferred Stock remain subject to certain beneficial ownership limitations described in the issuer's filings with the Securities and Exchange Commission. At the time of the Automatic Conversion, all of the shares of Series B Preferred Stock beneficially owned by the reporting person converted into shares of common stock. F2 · ownership.nature: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any. Read SEC document |
| September 25, 2024 Filed Sep 27, 2024 20:13 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | Exercise / conversionSeries B Non-Voting Convertible Preferred Stock | 721,361 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001453687-24-000112 · wk-form4_1727468009.xml · nonDerivative · entry 3 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On September 20, 2024, the issuer held a special meeting of stockholders (the "Special Meeting"). At the Special Meeting, the stockholders of the issuer approved the conversion of the issuer's Series B Non-Voting Convertible Preferred Stock ("Series B Preferred Stock") into shares of common stock. On September 25, 2024, the conversion of the majority of the shares of Series B Preferred Stock occurred automatically (the "Automatic Conversion"). The remaining shares of Series B Preferred Stock remain subject to certain beneficial ownership limitations described in the issuer's filings with the Securities and Exchange Commission. At the time of the Automatic Conversion, all of the shares of Series B Preferred Stock beneficially owned by the reporting person converted into shares of common stock. F2 · ownership.nature: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any. Read SEC document |
| September 25, 2024 Filed Sep 27, 2024 20:13 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | Exercise / conversionCommon Stock | 1,636,832 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001453687-24-000112 · wk-form4_1727468009.xml · nonDerivative · entry 2 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,016,731 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On September 20, 2024, the issuer held a special meeting of stockholders (the "Special Meeting"). At the Special Meeting, the stockholders of the issuer approved the conversion of the issuer's Series B Non-Voting Convertible Preferred Stock ("Series B Preferred Stock") into shares of common stock. On September 25, 2024, the conversion of the majority of the shares of Series B Preferred Stock occurred automatically (the "Automatic Conversion"). The remaining shares of Series B Preferred Stock remain subject to certain beneficial ownership limitations described in the issuer's filings with the Securities and Exchange Commission. At the time of the Automatic Conversion, all of the shares of Series B Preferred Stock beneficially owned by the reporting person converted into shares of common stock. Read SEC document |
| September 25, 2024 Filed Sep 27, 2024 20:13 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | Exercise / conversionSeries B Non-Voting Convertible Preferred Stock | 1,636,832 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001453687-24-000112 · wk-form4_1727468009.xml · nonDerivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On September 20, 2024, the issuer held a special meeting of stockholders (the "Special Meeting"). At the Special Meeting, the stockholders of the issuer approved the conversion of the issuer's Series B Non-Voting Convertible Preferred Stock ("Series B Preferred Stock") into shares of common stock. On September 25, 2024, the conversion of the majority of the shares of Series B Preferred Stock occurred automatically (the "Automatic Conversion"). The remaining shares of Series B Preferred Stock remain subject to certain beneficial ownership limitations described in the issuer's filings with the Securities and Exchange Commission. At the time of the Automatic Conversion, all of the shares of Series B Preferred Stock beneficially owned by the reporting person converted into shares of common stock. Read SEC document |
| September 24, 2024 Filed Sep 26, 2024 22:15 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | OtherCommon Stock | 186,134 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-024003 · form4-09262024_100948.xml · nonDerivative · entry 3 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 186,134 F3 · kind: Represents the acquisition of the shares from TAS, as more specifically described in Footnote (1) herein. Read SEC document |
| September 24, 2024 Filed Sep 26, 2024 22:15 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | OtherCommon Stock | 1,054,759 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-024003 · form4-09262024_100948.xml · nonDerivative · entry 2 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,746,764 F3 · kind: Represents the acquisition of the shares from TAS, as more specifically described in Footnote (1) herein. Read SEC document |
| September 24, 2024 Filed Sep 26, 2024 22:15 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | OtherCommon Stock | 1,240,893 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-024003 · form4-09262024_100948.xml · nonDerivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By LLC Disclosed balance after: 310,223 F1 · kind: Represents a distribution in kind, for no additional consideration, by TAS Partners, LLC ("TAS") to the Reporting Person and his spouse. F2 · ownership.nature: These shares are held by TAS. The Reporting Person is the sole managing member of TAS and, as such, has sole voting and dispositive power over the shares held by TAS. The Reporting Person disclaims beneficial ownership of the shares held by TAS except to the extent of his pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 23:10 UTC | Morphic Holding, Inc. MORF · Entity 88114 | Disposition to issuerStock Option (Right to Buy) · Derivative | 23,168 | Not disclosed Strike: $30.52 | Not disclosed |
DisclosureSEC source: 0001415889-24-021765 · form4-08202024_110817.xml · derivative · entry 11 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,168 shares Expires 2034-06-03 F5 · price: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F6 · derivative.exercise_date: The Option will vest in full on the earlier of (a) June 04, 2025 and (b) the next annual meeting of the issuer's stockholders, subject to the reporting person's provision of service to the issuer on the vesting date. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 23:10 UTC | Morphic Holding, Inc. MORF · Entity 88114 | Disposition to issuerStock Option (Right to Buy) · Derivative | 12,535 | Not disclosed Strike: $56.47 | Not disclosed |
DisclosureSEC source: 0001415889-24-021765 · form4-08202024_110817.xml · derivative · entry 10 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,535 shares Expires 2033-05-31 F5 · price: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F4 · derivative.exercise_date: The Company Stock Option ("Option") is fully vested. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 23:10 UTC | Morphic Holding, Inc. MORF · Entity 88114 | Disposition to issuerStock Option (Right to Buy) · Derivative | 17,550 | Not disclosed Strike: $24.49 | Not disclosed |
DisclosureSEC source: 0001415889-24-021765 · form4-08202024_110817.xml · derivative · entry 9 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,550 shares Expires 2032-06-08 F5 · price: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F4 · derivative.exercise_date: The Company Stock Option ("Option") is fully vested. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 23:10 UTC | Morphic Holding, Inc. MORF · Entity 88114 | Disposition to issuerStock Option (Right to Buy) · Derivative | 9,996 | Not disclosed Strike: $64.79 | Not disclosed |
DisclosureSEC source: 0001415889-24-021765 · form4-08202024_110817.xml · derivative · entry 8 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,996 shares Expires 2031-06-16 F5 · price: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F4 · derivative.exercise_date: The Company Stock Option ("Option") is fully vested. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 23:10 UTC | Morphic Holding, Inc. MORF · Entity 88114 | Disposition to issuerStock Option (Right to Buy) · Derivative | 12,000 | Not disclosed Strike: $22.96 | Not disclosed |
DisclosureSEC source: 0001415889-24-021765 · form4-08202024_110817.xml · derivative · entry 7 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2030-06-18 F5 · price: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F4 · derivative.exercise_date: The Company Stock Option ("Option") is fully vested. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 23:10 UTC | Morphic Holding, Inc. MORF · Entity 88114 | Disposition to issuerStock Option (Right to Buy) · Derivative | 90,000 | Not disclosed Strike: $15.72 | Not disclosed |
DisclosureSEC source: 0001415889-24-021765 · form4-08202024_110817.xml · derivative · entry 6 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 90,000 shares Expires 2029-12-05 F5 · price: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F4 · derivative.exercise_date: The Company Stock Option ("Option") is fully vested. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 23:10 UTC | Morphic Holding, Inc. MORF · Entity 88114 | Disposition to issuerStock Option (Right to Buy) · Derivative | 24,000 | Not disclosed Strike: $15.00 | Not disclosed |
DisclosureSEC source: 0001415889-24-021765 · form4-08202024_110817.xml · derivative · entry 5 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,000 shares Expires 2029-06-26 F5 · price: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F4 · derivative.exercise_date: The Company Stock Option ("Option") is fully vested. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 23:10 UTC | Morphic Holding, Inc. MORF · Entity 88114 | Disposition to issuerStock Option (Right to Buy) · Derivative | 4,288 | Not disclosed Strike: $7.76 | Not disclosed |
DisclosureSEC source: 0001415889-24-021765 · form4-08202024_110817.xml · derivative · entry 4 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,288 shares Expires 2029-04-11 F5 · price: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F4 · derivative.exercise_date: The Company Stock Option ("Option") is fully vested. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 23:10 UTC | Morphic Holding, Inc. MORF · Entity 88114 | OtherCommon Stock | 42,873 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-021765 · form4-08202024_110817.xml · nonDerivative · entry 3 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 0 F1 · price: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2 · price: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 23:10 UTC | Morphic Holding, Inc. MORF · Entity 88114 | OtherCommon Stock | 2,768,893 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-021765 · form4-08202024_110817.xml · nonDerivative · entry 2 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See TAS Partners LLC Disclosed balance after: 0 F1 · price: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2 · price: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding. F3 · ownership.nature: The reporting person is the manager of TAS Partners LLC and has sole voting and dispositive power over such shares. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 23:10 UTC | Morphic Holding, Inc. MORF · Entity 88114 | OtherCommon Stock | 4,608,052 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-021765 · form4-08202024_110817.xml · nonDerivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2 · price: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 20:43 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | PurchaseCommon Stock | 8,016 | $12.72 | $101,967.53 |
DisclosureSEC source: 0001453687-24-000106 · wk-form4_1723668232.xml · nonDerivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By wife Disclosed balance after: 11,509 F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $12.48 to $13.05. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| July 02, 2024 Filed Jul 5, 2024 20:02 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | GrantSeries B Non-Voting Convertible Preferred Stock | 1,307 | $20.00 | $26,140.00 |
DisclosureSEC source: 0001453687-24-000095 · wk-form4_1720209722.xml · nonDerivative · entry 3 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By wife Disclosed balance after: 1,307 Read SEC document |
| July 02, 2024 Filed Jul 5, 2024 20:02 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | GrantSeries B Non-Voting Convertible Preferred Stock | 721,361 | $20.00 | $14,427,220.00 |
DisclosureSEC source: 0001453687-24-000095 · wk-form4_1720209722.xml · nonDerivative · entry 2 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 721,361 F1 · ownership.nature: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any. Read SEC document |
| July 02, 2024 Filed Jul 5, 2024 20:02 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | GrantSeries B Non-Voting Convertible Preferred Stock | 1,636,832 | $20.00 | $32,736,640.00 |
DisclosureSEC source: 0001453687-24-000095 · wk-form4_1720209722.xml · nonDerivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,636,832 Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 20:30 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | GrantStock Option (Right to Buy) · Derivative | 11,760 | $0.00 Strike: $16.80 | $0.00 |
DisclosureSEC source: 0001415889-24-017984 · form4-06242024_080610.xml · derivative · entry 3 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,760 Underlying: Common Stock · 11,760 shares Expires 2034-06-19 F4 · derivative.exercise_date: 1/3rd of the shares subject to the option will vest on June 20, 2025, and the balance will vest in equal monthly installments thereafter over the next 24 months, subject in each case to the continuous service of the Reporting Person to the Issuer through the applicable vesting date. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 20:30 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | GrantCommon Stock | 1,551,116 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-017984 · form4-06242024_080610.xml · nonDerivative · entry 2 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By LLC Disclosed balance after: 1,551,116 F2 · price: Received in exchange for 2,902,429 shares of common stock of Tectonic on the same terms and conditions as set forth in footnote (1) herein. F3 · ownership.nature: These shares are held by TAS Partners, LLC ("TAS"). The Reporting Person is the sole managing member of TAS and, as such, has sole voting and dispositive power over the shares held by TAS. The Reporting Person disclaims beneficial ownership of the shares held by TAS except to the extent of his pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 20:30 UTC | Tectonic Therapeutic, Inc. TECX · Entity 5328 | GrantCommon Stock | 2,692,005 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-017984 · form4-06242024_080610.xml · nonDerivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,692,005 F1 · price: Received in exchange for 5,037,245 shares of common stock of Tectonic Therapeutic, Inc., a Delaware corporation ("Tectonic"), pursuant to an Agreement and Plan of Merger dated as of January 30, 2024 (the "Merger Agreement") by and among AVROBIO, Inc., a Delaware corporation ("AVROBIO"), Tectonic and Alpine Merger Subsidiary, Inc., a direct, wholly owned subsidiary of AVROBIO (the "Merger Sub"). Under the terms of the Merger Agreement, on June 20, 2024, Merger Sub merged with and into Tectonic (the "Merger"), with Tectonic surviving the Merger as a wholly owned subsidiary of AVROBIO. Upon the closing of the Merger, each share of Tectonic common stock was converted into the right to receive 0.534419990 shares of the Issuer's common stock, after giving effect to a reverse stock split of the Issuer's common stock of 1-for-12. Subsequent to the Merger, the name of the Issuer was changed from AVROBIO, Inc. to Tectonic Therapeutic, Inc. Read SEC document |
| June 04, 2024 Filed Jun 5, 2024 23:14 UTC | Morphic Holding, Inc. MORF · Entity 88114 | GrantCommon Stock · Derivative | 23,168 | $0.00 Strike: $30.52 | $0.00 |
DisclosureSEC source: 0001415889-24-015670 · form4-06052024_110616.xml · derivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,168 Underlying: Common Stock · 23,168 shares Expires 2034-06-03 F1 · derivative.exercise_date: The option will vest in full on the earlier of (a) June 04, 2025 and (b) the next annual meeting of the issuer's stockholders, subject to the reporting person's provision of service to the issuer on the vesting date. Read SEC document |
| April 08, 2024 Filed Apr 11, 2024 01:40 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | Exercise / conversionCommon Stock | 826,169 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001453687-24-000063 · wk-form4_1712799609.xml · nonDerivative · entry 4 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 1,927,630 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On March 27, 2024, the issuer held a special meeting of stockholders (the "Special Meeting"). At the Special Meeting, the stockholders of the issuer approved a 1-for-30 reverse stock split (the "Reverse Stock Split") of the issuer's common stock ("Common Stock") and the conversion of the issuer's Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") into shares of Common Stock. On April 8, 2024, the conversion of the majority of the shares of Series A Preferred Stock occurred automatically (the "Automatic Conversion"). The remaining shares of Series A Preferred Stock remain subject to certain beneficial ownership limitations described in the issuer's filings with the Securities and Exchange Commission. At the time of the Automatic Conversion, all of the reporting person's shares of Series A Preferred Stock converted into shares of Common Stock. F2 · balance_after: On April 4, 2024, the issuer effected the "Reverse Stock Split". The amount of securities reported on this Form 4 has been adjusted to reflect the Reverse Stock Split. F3 · ownership.nature: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 08, 2024 Filed Apr 11, 2024 01:40 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | Exercise / conversionSeries A Non-Voting Convertible Preferred Stock | 24,785.081 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001453687-24-000063 · wk-form4_1712799609.xml · nonDerivative · entry 3 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On March 27, 2024, the issuer held a special meeting of stockholders (the "Special Meeting"). At the Special Meeting, the stockholders of the issuer approved a 1-for-30 reverse stock split (the "Reverse Stock Split") of the issuer's common stock ("Common Stock") and the conversion of the issuer's Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") into shares of Common Stock. On April 8, 2024, the conversion of the majority of the shares of Series A Preferred Stock occurred automatically (the "Automatic Conversion"). The remaining shares of Series A Preferred Stock remain subject to certain beneficial ownership limitations described in the issuer's filings with the Securities and Exchange Commission. At the time of the Automatic Conversion, all of the reporting person's shares of Series A Preferred Stock converted into shares of Common Stock. F3 · ownership.nature: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 08, 2024 Filed Apr 11, 2024 01:40 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | Exercise / conversionCommon Stock | 4,130,846 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001453687-24-000063 · wk-form4_1712799609.xml · nonDerivative · entry 2 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,379,899 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On March 27, 2024, the issuer held a special meeting of stockholders (the "Special Meeting"). At the Special Meeting, the stockholders of the issuer approved a 1-for-30 reverse stock split (the "Reverse Stock Split") of the issuer's common stock ("Common Stock") and the conversion of the issuer's Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") into shares of Common Stock. On April 8, 2024, the conversion of the majority of the shares of Series A Preferred Stock occurred automatically (the "Automatic Conversion"). The remaining shares of Series A Preferred Stock remain subject to certain beneficial ownership limitations described in the issuer's filings with the Securities and Exchange Commission. At the time of the Automatic Conversion, all of the reporting person's shares of Series A Preferred Stock converted into shares of Common Stock. F2 · balance_after: On April 4, 2024, the issuer effected the "Reverse Stock Split". The amount of securities reported on this Form 4 has been adjusted to reflect the Reverse Stock Split. Read SEC document |
| April 08, 2024 Filed Apr 11, 2024 01:40 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | Exercise / conversionSeries A Non-Voting Convertible Preferred Stock | 123,925.407 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001453687-24-000063 · wk-form4_1712799609.xml · nonDerivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On March 27, 2024, the issuer held a special meeting of stockholders (the "Special Meeting"). At the Special Meeting, the stockholders of the issuer approved a 1-for-30 reverse stock split (the "Reverse Stock Split") of the issuer's common stock ("Common Stock") and the conversion of the issuer's Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") into shares of Common Stock. On April 8, 2024, the conversion of the majority of the shares of Series A Preferred Stock occurred automatically (the "Automatic Conversion"). The remaining shares of Series A Preferred Stock remain subject to certain beneficial ownership limitations described in the issuer's filings with the Securities and Exchange Commission. At the time of the Automatic Conversion, all of the reporting person's shares of Series A Preferred Stock converted into shares of Common Stock. Read SEC document |
| March 26, 2024 Filed Mar 26, 2024 20:32 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | Exercise / conversionWarrant (Right to Buy) · Derivative | 1,970,443 | $0.00 Strike: $1.46 | $0.00 |
DisclosureSEC source: 0001453687-24-000045 · wk-form4_1711485128.xml · derivative · entry 4 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,970,443 shares Expires 2024-12-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any. Read SEC document |
| March 26, 2024 Filed Mar 26, 2024 20:32 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | Exercise / conversionCommon Stock | 1,970,443 | $1.46 | $2,876,846.78 |
DisclosureSEC source: 0001453687-24-000045 · wk-form4_1711485128.xml · nonDerivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 33,043,849 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 21:09 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | PurchaseCommon Stock | 19,044 | $0.60 | $11,397.83 |
DisclosureSEC source: 0001453687-24-000043 · wk-form4_1710968926.xml · nonDerivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 31,073,406 F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $0.575 to $0.60. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.